{"id":517395,"date":"2021-07-26T08:04:26","date_gmt":"2021-07-26T12:04:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/"},"modified":"2021-07-26T08:04:26","modified_gmt":"2021-07-26T12:04:26","slug":"akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/","title":{"rendered":"Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n CAMBRIDGE, Mass.<\/span>, July 26, 2021<\/span> \/PRNewswire\/ — Akebia Therapeutics, Inc.<\/a> (Nasdaq: AKBA),\u00a0a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2021<\/span>, on Thursday, August 5, 2021<\/span> before the opening of the financial markets. <\/p>\n

\n

\n
\n \"Akebia
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday<\/span>, August 5, to discuss its second quarter financial results and recent business highlights. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number\u00a05529396. The call will also be webcast LIVE and can be accessed via the Investors section of the Company’s website at\u00a0http:\/\/ir.akebia.com<\/a>. <\/p>\n

A replay of the conference call will be available two hours after the completion of the call through\u00a0August 11, 2021. To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference conference ID number\u00a05529396. An online archive of the conference call can be accessed via the Investors section of the Company’s website at\u00a0http:\/\/ir.akebia.com<\/a>.<\/p>\n

\u00a0About Akebia Therapeutics
<\/b>Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts<\/span>. For more information, please visit our website at https:\/\/akebia.com\/<\/a> which does not form a part of this release.<\/p>\n

Investor Contact
Kristen K. Sheppard, Esq.<\/span>
ir@akebia.com<\/a><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights-301340605.html<\/a><\/p>\n

SOURCE Akebia Therapeutics<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire CAMBRIDGE, Mass., July 26, 2021 \/PRNewswire\/ — Akebia Therapeutics, Inc. (Nasdaq: AKBA),\u00a0a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2021, on Thursday, August 5, 2021 before the opening of the financial markets. Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, August 5, to discuss its second quarter financial results and recent business highlights. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number\u00a05529396. The call will also be webcast LIVE and can be accessed via the Investors section of the Company’s … <\/p>\n

Continue reading “Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-517395","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAkebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire CAMBRIDGE, Mass., July 26, 2021 \/PRNewswire\/ — Akebia Therapeutics, Inc. (Nasdaq: AKBA),\u00a0a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2021, on Thursday, August 5, 2021 before the opening of the financial markets. Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, August 5, to discuss its second quarter financial results and recent business highlights. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number\u00a05529396. The call will also be webcast LIVE and can be accessed via the Investors section of the Company’s … Continue reading "Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-26T12:04:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights\",\"datePublished\":\"2021-07-26T12:04:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\\\/\"},\"wordCount\":270,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1136400\\\/Akebia_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\\\/\",\"name\":\"Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1136400\\\/Akebia_Logo.jpg\",\"datePublished\":\"2021-07-26T12:04:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1136400\\\/Akebia_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1136400\\\/Akebia_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/","og_locale":"en_US","og_type":"article","og_title":"Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights - Market Newsdesk","og_description":"PR Newswire CAMBRIDGE, Mass., July 26, 2021 \/PRNewswire\/ — Akebia Therapeutics, Inc. (Nasdaq: AKBA),\u00a0a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2021, on Thursday, August 5, 2021 before the opening of the financial markets. Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, August 5, to discuss its second quarter financial results and recent business highlights. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number\u00a05529396. The call will also be webcast LIVE and can be accessed via the Investors section of the Company’s … Continue reading \"Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-26T12:04:26+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights","datePublished":"2021-07-26T12:04:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/"},"wordCount":270,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/","name":"Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg","datePublished":"2021-07-26T12:04:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss-recent-business-highlights\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/517395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=517395"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/517395\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=517395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=517395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=517395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}